What question did this study set out to answer?

This research investigates the role of VPS35 as a biomarker in liver cancer (LIHC).

January 14, 2026RSC Medicinal Chemistry0 citationsOpen Access

Comprehensive multi-omics analysis and experimental validation indicate that VPS35 is a promising biomarker for prognosis, immunotherapy, and chemotherapy in LIHC

DWDan WanShaanxi Provincial People's Hospital YQYajie QiSecond Affiliated Hospital of Xi'an Jiaotong University YKYali KangShaanxi Provincial People's Hospital

Key Points

This research investigates the role of VPS35 as a biomarker in liver cancer (LIHC).
Comprehensive multi-omics analysis conducted
Experimental validation of VPS35 expression
Targeted knockdown of VPS35 performed to assess effects
VPS35 is identified as a promising biomarker for prognosis
Higher expression of VPS35 correlates with better diagnostic value
Inhibition of VPS35 may enhance immunotherapy and chemotherapy outcomes

Abstract

Vacuolar protein sorting 35 ( VPS35 ) is highly expressed in LIHC and exhibits significant diagnostic and prognostic value. Targeted knockdown of VPS35 may inhibit LIHC progression and enhance the efficacy of immunotherapy and chemotherapy.

问 AI

Bookmark

View Full Paper